Inclusion Criteria:

• Informed consent

- Age > 18 years

- Performance status 0-1; expected survival ≥ 3 months

- Patient with histologically or cytologically adenocarcinoma developed from cells in
the gall bladder, extra- or intrahepatic bile ducts or malignant cells consistent
with above mentioned and radiologic findings consistent with cholangiocarcinoma

- Liver metastases not suitable for surgery or other local treatment

- Extrahepatic disease should be excluded by PET-CT-scan.

- Prior treatment with chemotherapy or no progression on first line treatment

- Metastases < 70 % of the liver

- neutrophile granulocytes ≥ 1.5 x 109/l og thrombocytes ≥ 100 x 109/l

- bilirubin < 2.0 x UNL (upper normal limit).

- creatinine-clearance ≥ 30 ml/min.

- INR < 2.

- Intrahepatic treatment can be accomplished

- The patients is approved by a multidisciplinary team

Exclusion Criteria:• Other current or prior malignant disease except adequately treated
and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin.

- Cytotoxic or experimental treatment within a 14 days period before start of trial
medication

- The patient is not allowed to participate in other clinical trials.

- Any clinical symptoms suggesting peripheral neuropathy grade 2

- Other severe medical conditions

- Severe cardial disease or AMI < 1 year

- Presence of diseases preventing oral therapy

- Patients with uncontrolled infection

- Pregnant or lactating women

- Women capable of childbearing not using a sufficient method of birth control

- Patients not able to understand the treatment or to collaborate

- Prior serious or unsuspected reaction after treatment with fluoropyrimidine

- Known prior hypersensitivity reactions to the agents

- Interstitial pneumonitis or pulmonary fibrosis